Inspire Medical Systems, Inc. (INSP) FY2026 YTD Q2 Statement of Cash Flows

Statement of Cash Flows

2026-01-01 to 2026-06-30

Swipe to see the full flow
Inspire Medical Systems, Inc. cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Stock-based compensation expense → operating reconciliation: $61,915,000.00Accounts receivable → operating reconciliation: $16,212,000.00Deferred income tax expense → operating reconciliation: $11,161,000.00Depreciation and amortization → operating reconciliation: $9,707,000.00Other non-cash expenses → operating reconciliation: $741,000.00operating reconciliation → Net cash from operating activities: $36,077,000.00operating reconciliation → Net (loss): $10,980,000.00operating reconciliation → Inventories: $25,159,000.00operating reconciliation → Accrued expenses and other liabilities: $16,227,000.00operating reconciliation → Accounts payable: $6,699,000.00operating reconciliation → Prepaid expenses and other current assets: $4,067,000.00operating reconciliation → Accretion of investment discount: $527,000.00Proceeds from sales or maturities of investments → investing reconciliation: $93,431,000.00Net cash used in investing activities → investing reconciliation: $7,701,000.00investing reconciliation → Purchases of investments: $82,246,000.00investing reconciliation → Capital expenditures: $18,886,000.00Net cash used in financing activities → financing reconciliation: $5,571,000.00Proceeds from issuance of common stock from employee stock purchase plan → financing reconciliation: $2,193,000.00Proceeds from the exercise of stock options → financing reconciliation: $512,000.00financing reconciliation → Payment of taxes on net share settlement of equity awards: $8,276,000.00Exchange-rate effect → Cash sources and uses: $143,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $104,813,000.00Net cash from operating activities → Cash sources and uses: $36,077,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $127,761,000.00Cash sources and uses → Net cash used in investing activities: $7,701,000.00Cash sources and uses → Net cash used in financing activities: $5,571,000.00Net (loss): -$10,980,000.00Net (loss)−$10.98 MDepreciation and amortization: $9,707,000.00Depreciation & amortization+$9.71 MDeferred income tax expense: $11,161,000.00Deferred income taxes+$11.16 MAccretion of investment discount: -$527,000.00Investment discount & premium−$527.00 KStock-based compensation expense: $61,915,000.00Stock-based compensation+$61.92 MAccounts receivable: $16,212,000.00Receivables, net+$16.21 MInventories: -$25,159,000.00Inventories−$25.16 MPrepaid expenses and other current assets: -$4,067,000.00Prepaid & other assets−$4.07 MAccounts payable: -$6,699,000.00Accounts payable−$6.70 MAccrued expenses and other liabilities: -$16,227,000.00Accrued & other liabilities−$16.23 MOther non-cash expenses: $741,000.00Other non-cash expenses+$741.00 KImpairment charge: $0.00Net cash from operating activities: $36,077,000.00Operating cash+$36.08 Moperating reconciliation: $99,736,000.00Proceeds from the exercise of stock options: $512,000.00Stock option exercises+$512.00 KShare repurchase of common stock: $0.00Payment of taxes on net share settlement of equity awards: -$8,276,000.00Stock-award tax withholding−$8.28 MProceeds from issuance of common stock from employee stock purchase plan: $2,193,000.00Employee stock purchase proceeds+$2.19 MNet cash used in financing activities: -$5,571,000.00. Cash required to fund net payments.Financing cash−$5.57 Mfinancing reconciliation: $8,276,000.00Capital expenditures: -$18,886,000.00PP&E purchases−$18.89 MProceeds from sales or maturities of investments: $93,431,000.00Investment sales & maturities+$93.43 MPurchases of investments: -$82,246,000.00AFS securities purchases−$82.25 MNet cash used in investing activities: -$7,701,000.00. Cash required to fund net payments.Investing cash−$7.70 Minvesting reconciliation: $101,132,000.00Cash sources and uses: $141,033,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $104,813,000.00Beginning cash$104.81 MEnding cash: Cash, cash equivalents, and restricted cash: $127,761,000.00Ending cash$127.76 MExchange-rate effect: $143,000.00FX effect+$143.00 KCASH RECONCILIATIONOperatingflowsInvestingflowsFinancingflowsNet loss −$10.98M + net operating adjustments $47.06M = operating cash +$36.08MFree cash flow$17.19 MOperating cash − cash spent on PP&ECash flow / Net incomeNot meaningfulOperating cash flow ÷ net incomeNet cash change+$22.95 MEnding cash − beginning cash
Chart details

Inspire Medical Systems, Inc. cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026

Cash flows for Jan 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2025. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Dec 31, 2025
104,813,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
36,077,000 US dollars. Net cash provided.
Net (loss)
negative 10,980,000 US dollars
Depreciation and amortization
9,707,000 US dollars
Deferred income tax expense
11,161,000 US dollars
Accretion of investment discount
negative 527,000 US dollars
Stock-based compensation expense
61,915,000 US dollars
Accounts receivable
16,212,000 US dollars
Inventories
negative 25,159,000 US dollars
Prepaid expenses and other current assets
negative 4,067,000 US dollars
Accounts payable
negative 6,699,000 US dollars
Accrued expenses and other liabilities
negative 16,227,000 US dollars
Other non-cash expenses
741,000 US dollars
Impairment charge
0 US dollars
Investing activities
negative 7,701,000 US dollars. Net cash used.
Capital expenditures
negative 18,886,000 US dollars
Proceeds from sales or maturities of investments
93,431,000 US dollars
Purchases of investments
negative 82,246,000 US dollars
Financing activities
negative 5,571,000 US dollars. Net cash used.
Proceeds from the exercise of stock options
512,000 US dollars
Share repurchase of common stock
0 US dollars
Payment of taxes on net share settlement of equity awards
negative 8,276,000 US dollars
Proceeds from issuance of common stock from employee stock purchase plan
2,193,000 US dollars
Operating adjustment reconciliation
99,736,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
8,276,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
101,132,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
143,000 US dollars
Ending cash on Jun 30, 2026
127,761,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
141,033,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
22,948,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
Not meaningful. Operating cash flow divided by reconciliation net income for the same period. The ratio is not meaningful when net income is zero or negative.
Operating cash flow
36,077,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
18,886,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
17,191,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net loss −$10.98M + net operating adjustments $47.06M = operating cash +$36.08M. The loss reduces the earnings basis of the reconciliation; it is not a cash payment. The signed loss remains a deduction at the operating reconciliation junction.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 36,077,000 US dollars minus 18,886,000 US dollars equals 17,191,000 US dollars.
Inspire Medical Systems, Inc. (INSP) FY2026 YTD Q2 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!